We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Kraig Biocraft Laboratories Inc (QB) | USOTC:KBLB | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.00075 | -0.83% | 0.09 | 0.0867 | 0.0939 | 0.0938 | 0.0864 | 0.0909 | 255,625 | 21:08:13 |
Wyoming
|
|
83-0459707
|
(State
or Other Jurisdiction of Incorporation)
|
|
(I.R.S.
Employer Identification No.)
|
2723
South State St. Suite 150
Ann
Arbor, Michigan 48104
|
|
(734)
619-8066
|
(Address
of Principal Executive Offices)
|
|
(Registrant’s
Telephone Number)
|
Large
Accelerated Filer [ ]
|
|
Accelerated
Filer [ ]
|
Non-Accelerated
Filer [ ]
Emerging
Growth Company [ ]
|
(Do not
check if a smaller reporting company)
|
Smaller
reporting company [X]
|
|
|
Page
|
PART I
|
|
3
|
|
|
|
ITEM
1.
|
DESCRIPTION
OF BUSINESS
|
3
|
ITEM
1A.
|
RISK
FACTORS
|
7
|
ITEM
1B.
|
UNRESOLVED
STAFF COMMENTS
|
7
|
ITEM
2.
|
DESCRIPTION
OF PROPERTY
|
7
|
ITEM
3.
|
LEGAL
PROCEEDINGS
|
7
|
ITEM
4.
|
MINE
SAFETY DISCLOSURES
|
7
|
|
|
|
PART II
|
|
7
|
|
|
|
ITEM
5.
|
MARKET
FOR REGISTRANT’S COMMON EQUITY; RELATED STOCKHOLDER MATTERS
AND ISSUER PURCHASES
|
7
|
ITEM
6.
|
SELECTED
FINANCIAL DATA
|
9
|
ITEM
7.
|
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
|
9
|
ITEM
7A.
|
QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|
14
|
ITEM
8.
|
FINANCIAL
STATEMENTS AND SUPPLEMENTARY DATA
|
14
|
ITEM
9.
|
CHANGES
IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL
DISCLOSURE
|
34
|
ITEM
9A.
|
CONTROLS
AND PROCEDURES
|
35
|
ITEM
9B.
|
OTHER
INFORMATION
|
36
|
|
|
|
PART III
|
|
36
|
|
|
|
ITEM
10.
|
DIRECTORS,
EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
|
36
|
ITEM
11.
|
EXECUTIVE
COMPENSATION
|
37
|
ITEM
12.
|
SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED
STOCKHOLDER MATTERS
|
39
|
ITEM
13.
|
CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE
|
39
|
ITEM
14.
|
PRINCIPAL
ACCOUNTANT FEES AND SERVICES
|
40
|
|
|
|
PART IV
|
|
41
|
|
|
|
ITEM
15.
|
EXHIBITS
|
41
|
|
|
|
SIGNATURES
|
|
42
|
●
|
Medical
textiles;
|
●
|
Geotextiles;
|
●
|
Textiles
used in Defense and Military;
|
●
|
Safe
and Protective Clothing;
|
●
|
Filtration
Textiles;
|
●
|
Textiles
used in Transportation;
|
●
|
Textiles
used in Buildings;
|
●
|
Composites
with Textile Structure;
|
●
|
Functional
and Sportive Textiles.
|
|
Material Toughness (1)
|
Tensile Strength (2)
|
Weight (3)
|
Dragline
spider silk
|
120,000-160,000
|
1,100-2,900
|
1.18-1.36
|
|
|
|
|
Steel
|
2,000-6,000
|
300-2,000
|
7.84
|
1
|
Measured
by the energy required to break a continuous filament, expressed in
joules per kilogram (J/kg). A .357 caliber bullet has approximately
925 joules of kinetic energy at impact.
|
|
|
2
|
Tensile
strength refers to the greatest longitudinal stress the fiber can
bear, measured by force over area in units of newtons per square
meter. The measurement here is in millions of pascals.
|
|
|
3
|
In
grams per cubic centimeter of material.
|
Marks
|
Registered Owner
|
Country
|
Status
|
Monster
SilkTM
|
Kraig
Biocraft Laboratories
|
United
States of America
|
issued
|
SpiderpillarTM
|
Kraig
Biocraft Laboratories
|
United
States of America
|
issued
|
SpilkTM
|
Kraig
Biocraft Laboratories
|
United
States of America
|
issued
|
Monster
WormTM
|
Kraig
Biocraft Laboratories
|
United
States of America
|
issued
|
Spider
WormTM
|
Kraig
Biocraft Laboratories
|
United
States of America
|
issued
|
Spider
MothTM
|
Kraig
Biocraft Laboratories
|
United
States of America
|
issued
|
|
Low
Price
|
High
Price
|
Fourth Quarter
2017
|
$
0.034
|
$
0.055
|
Third Quarter
2017
|
$
0.045
|
$
0.07
|
Second Quarter
2017
|
$
0.052
|
$
0.08
|
First Quarter
2017
|
$
0.051
|
$
0.087
|
|
|
|
|
|
|
Fourth Quarter
2016
|
$
0.04
|
$
0.056
|
Third Quarter
2016
|
$
0.019
|
$
0.095
|
Second Quarter
2016
|
$
0.014
|
$
0.025
|
First Quarter
2016
|
$
0.022
|
$
0.027
|
|
|
|
●
|
|
We have
spent approximately $258,892 between January 2017 and December 2017
on collaborative research and development of high strength polymers
at the University of Notre Dame. We plan to accelerate both our
microbiology and selective breeding programs as well as providing
more resources for our material testing protocols in 2018. We are
currently reviewing plans for research spending for 2018. We expect
to continue funding the collaborative research and development at
the University of Notre Dame.
|
●
|
|
We
expect to spend approximately $13,700 on collaborative research and
development at the University of Wyoming over the next twelve
months. This level of research spending at the university is also a
requirement of our licensing agreement with them.
|
●
|
|
We will
actively consider pursuing collaborative research opportunities
with other university laboratories in the area of high strength
polymers. If our financing allows, management will give strong
consideration to increasing the depth of our research to include
polymer production technologies that are closely related to our
core research.
|
●
|
|
We will
consider buying an established revenue producing company in a
compatible business, in order to broaden our financial base and
facilitate the commercialization of our products. We expect to use
a combination of stock and cash for any such purchase.
|
●
|
|
We will
also actively consider pursuing collaborative research
opportunities with both private and university laboratories in
areas of research which overlap the company’s existing
research and development. One such potential area for collaborative
research which the company is considering is protein expression
platforms. If our financing will allow, management will give strong
consideration to increasing the breadth of our research to include
protein expression platform technologies.
|
●
|
|
We plan
to actively pursue collaborative research and product testing,
opportunities with companies in the biotechnology, materials,
textile and other industries.
|
●
|
|
We plan
to actively pursue collaborative commercialization, marketing and
manufacturing opportunities with companies in the textile and
material sectors for the fibers we developed and for any new
polymers that we created in 2018.
|
●
|
|
We plan
to actively pursue the development of commercial scale production
of our recombinant materials including Monster SilkTM and
Dragon SilkTM.
|
|
Year Ended December 31
|
|
|
|
|
|
Increase
(Decrease)
|
%
Change
|
|
|
2017
|
2016
|
Change
|
|
NET
REVENUES
|
$
97,318
|
$
31,858
|
65,460
|
205.47
%
|
OPERATING
EXPENSES:
|
|
|
|
|
General
and Administrative
|
1,217,050
|
1,736,918
|
(519,868
)
|
-29.93
%
|
Professional
Fees
|
322,215
|
396,125
|
(73,910
)
|
-18.66
%
|
Officer's
Salary
|
444,596
|
447,283
|
(2,687
)
|
-0.60
%
|
Rent
- Related Party
|
10,560
|
-
|
10,560
|
100.00
%
|
Research
and Development
|
258,892
|
397,136
|
(138,244
)
|
-34.81
%
|
Total operating expenses
|
2,253,313
|
2,977,462
|
(724,149
)
|
-24.32
%
|
Loss from operations
|
(2,155,995
)
|
(2,945,604
)
|
789,609
|
-26.81
%
|
Gain
on forgiveness of debt
|
-
|
11,191
|
(11,191
)
|
-100.00
%
|
Interest
expense
|
(177,105
)
|
(139,430
)
|
(37,675
)
|
27.02
%
|
Net Loss
|
$
(2,333,100
)
|
$
(3,073,843
)
|
740,743
|
24.10
%
|
|
December 31, 2017
|
December 31, 2016
|
Cash
|
$
18,150
|
$
298,859
|
Accounts
receivable
|
$
25,872
|
$
31,858
|
Prepaid
expenses
|
$
4,465
|
$
1,074
|
Total
current assets
|
$
48,487
|
$
331,791
|
Total
assets
|
$
114,499
|
$
383,659
|
Total
current liabilities
|
$
3,490,305
|
$
2,744,472
|
Total
liabilities
|
$
3,490,305
|
$
2,744,472
|
PAGE
|
15
|
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
|
|
|
|
PAGE
|
16
|
BALANCE
SHEETS AS OF DECEMBER 31, 2017 AND DECEMBER 31, 2016.
|
|
|
|
PAGE
|
17
|
STATEMENTS
OF OPERATIONS FOR THE YEARS ENDED DECEMBER 31, 2017 AND DECEMBER
31, 2016.
|
|
|
|
PAGE
|
18
|
STATEMENTS
OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2017 AND DECEMBER
31, 2016.
|
|
|
|
PAGES
|
19
|
STATEMENT
OF CHANGES IN STOCKHOLDERS’ DEFICIT FOR THE PERIOD FROM
DECEMBER 31, 2016 TO DECEMBER 31, 2017.
|
|
|
|
PAGES
|
20
|
NOTES
TO FINANCIAL STATEMENTS.
|
/s/
M&K CPAS, PLLC
|
|
|
|
We have
served as the Company’s auditor since 2013.
|
|
|
|
Houston,
TX
|
|
|
|
March
23, 2018
|
|
Kraig
Biocraft Laboratories, Inc.
|
||
Statements
of Cash Flows
|
||
|
||
|
For
the Years Ended
|
|
|
December
31, 2017
|
December
31, 2016
|
Cash
Flows From Operating Activities:
|
|
|
Net
Loss
|
$
(2,333,100
)
|
$
(3,073,843
)
|
Adjustments
to reconcile net loss to net cash used in operations
|
|
|
Depreciation
expense
|
20,291
|
16,974
|
Gain on
forgiveness of debt
|
-
|
11,191
|
Imputed
interest - related party
|
2,623
|
1,425
|
Stock
issuable for services
|
-
|
32,850
|
Warrants
issued to consultants
|
848,011
|
1,356,230
|
Warrants
issued to related party
|
17,473
|
193,654
|
Changes in
operating assets and liabilities:
|
|
|
(Increase)
Decrease in prepaid expenses
|
(6,658
)
|
(679
)
|
(Increase)
Decrease in accounts receivables, net
|
5,986
|
(31,858
)
|
Increase in
accrued expenses and other payables - related party
|
551,237
|
498,640
|
Increase in
accounts payable
|
164,595
|
(16,425
)
|
Net
Cash Used In Operating Activities
|
(729,542
)
|
(1,011,841
)
|
|
|
|
Cash
Flows From Investing Activities:
|
|
|
Purchase of Fixed
Assets and Domain Name
|
(31,167
)
|
(2,488
)
|
Net
Cash Used In Investing Activities
|
(31,167
)
|
(2,488
)
|
|
|
|
Cash
Flows From Financing Activities:
|
|
|
Proceeds from Notes
Payable - related party
|
30,000
|
50,000
|
Proceeds from
issuance of common stock
|
450,000
|
1,025,000
|
Net
Cash Provided by Financing Activities
|
480,000
|
1,075,000
|
|
|
|
Net
Increase in Cash (decrease)
|
(280,709
)
|
60,671
|
|
|
|
Cash at Beginning
of Period
|
298,859
|
238,188
|
|
|
|
Cash
at End of Period
|
$
18,150
|
$
298,859
|
|
|
|
Supplemental
disclosure of cash flow information:
|
|
|
|
|
|
Cash paid for
interest
|
$
-
|
$
-
|
Cash paid for
taxes
|
$
-
|
$
-
|
|
|
|
Supplemental
disclosure of non-cash investing and financing
activities:
|
|
|
Shares
issued in connection with cashless warrants exercise
|
$
1,703,115
|
$
1,131,007
|
Shares issuable in connection with cashless warrant
exercise
|
$
-
|
$
224,904
|
Settlement of accounts payable with stock issuance
|
$
32,850
|
$
808
|
|
December
31, 2017
|
December
31 , 2016
|
Stock Warrants
(Exercise price - $0.001/share)
|
32,800,000
|
47,800,000
|
Convertible
Preferred Stock
|
2
|
2
|
Total
|
32,800,002
|
47,800,002
|
|
Years Ended
December,
|
|
|
2017
|
2016
|
|
|
|
Deferred tax
liability:
|
$
-
|
$
-
|
Deferred tax
asset
|
|
|
Net
Operating Loss Carryforward
|
4,334,248
|
3,835,342
|
Valuation
allowance
|
(4,334,248
)
|
(3,835,342
)
|
Net
deferred tax asset
|
-
|
-
|
Net
deferred tax liability
|
$
-
|
$
-
|
|
|
|
°
|
Level 1
- Valuations based on quoted prices in active markets for identical
assets or liabilities that an entity has the ability to
access. We believe our carrying value of level 1
instruments approximate their fair value at December 31, 2017 and
December 31, 2016.
|
°
|
Level 2
- Valuations based on quoted prices for similar assets or
liabilities, quoted prices for identical assets or liabilities in
markets that are not active, or other inputs that are observable or
can be corroborated by observable data for substantially the full
term of the assets or liabilities.
|
°
|
Level 3
- Valuations based on inputs that are supported by little or no
market activity and that are significant to the fair value of the
assets or liabilities. We consider depleting assets, asset
retirement obligations and net profit interest liability to be
Level 3. We determine the fair value of Level 3
assets and liabilities utilizing various inputs, including NYMEX
price quotations and contract terms.
|
|
December 31, 2017
|
December
31, 2016
|
Level
1
|
$
-
|
$
-
|
Level
2
|
$
-
|
$
-
|
Level
3
|
$
-
|
$
-
|
Total
|
$
-
|
$
-
|
Customer
|
December
31, 2017
|
December
31, 2016
|
Customer
A
|
100%
|
100
%
|
Customer
A
|
$
25,872
|
$
31,858
|
Customer
|
December
31, 2017
|
December
31, 2016
|
Customer
A
|
100
%
|
100
%
|
Customer
A
|
$
97,318
|
$
31,858
|
|
As
of December 31, 2017
|
As
of December 31, 2016
|
Automobile
|
$
41,805
|
$
41,805
|
Laboratory Equipment
|
61,746
|
39,310
|
Office Equipment
|
7,260
|
6,466
|
Leasehold
Improvements
|
7,938
|
-
|
Less: Accumulated
Depreciation
|
(56,255
)
|
(35,963
)
|
Total Property and Equipment,
net
|
$
62,494
|
$
51,618
|
Expected
dividends
|
0
%
|
Expected
volatility
|
78.58
%
|
Expected
term
|
3
years
|
Risk free
interest rate
|
1.32
%
|
Expected
forfeitures
|
0
%
|
Expected
dividends
|
0
%
|
Expected
volatility
|
93.6
%
|
Expected
term
|
4
years
|
Risk free
interest rate
|
1.01
%
|
Expected
forfeitures
|
0
%
|
Expected
dividends
|
0
%
|
Expected
volatility
|
93.60
%
|
Expected
term
|
4
years
|
Risk free
interest rate
|
1.01
%
|
Expected
forfeitures
|
0
%
|
Expected
dividends
|
0
%
|
Expected
volatility
|
107.51
%
|
Expected
term
|
2
years
|
Risk free
interest rate
|
0.82
%
|
Expected
forfeitures
|
0
%
|
Expected
dividends
|
0
%
|
Expected
volatility
|
106.57
%
|
Expected
term
|
2
years
|
Risk free
interest rate
|
1.15
%
|
Expected
forfeitures
|
0
%
|
Expected
dividends
|
0
%
|
Expected
volatility
|
106.40
%
|
Expected
term
|
3
years
|
Risk free
interest rate
|
1.43
%
|
Expected
forfeitures
|
0
%
|
Expected
dividends
|
0
%
|
Expected
volatility
|
102.65
%
|
Expected
term
|
2
years
|
Risk free
interest rate
|
1.38
%
|
Expected
forfeitures
|
0
%
|
|
Number
of
Warrants
|
Weighted
Average Exercise Price
|
Weighted
Average Remaining Contractual Life (in Years)
|
Balance,
December 31, 2016
|
47,800,000
|
$
0.001
|
3.8
|
Granted
|
15,750,000
|
$
0.03
|
|
Exercised
|
30,000,000
|
$
0.001
|
|
Cancelled/Forfeited
|
(750,000
)
|
$
0.03
|
|
Balance, December
31, 2017
|
32,800,000
|
|
3.0
|
Intrinsic
Value
|
$
1,426,800
|
|
|
Exercise
Price Warrants Outstanding
|
Warrants
Exercisable
|
Aggregate
Intrinsic Value
|
|
|
|
|
|
$
0.001
|
30,500,000
|
2.5
|
$
2,639,000
|
$
0.04
|
2,300,000
|
3.1
|
$
133,400
|
Exercise Price Warrants
Outstanding
|
Warrants
Exercisable
|
Weighted
Average Remaining Contractual Life
|
Aggregate
Intrinsic Value
|
|
|
|
|
$
0.001
|
45,500,000
|
4.1
|
$
2,434,250
|
$
0.04
|
2,300,000
|
5
|
$
123,050
|
●
|
Common
stock Class A, unlimited number of shares authorized, no par
value
|
●
|
Common
stock Class B, unlimited number of shares authorized, no par
value
|
●
|
Preferred
stock, unlimited number of shares authorized, no par
value
|
●
|
Calm
Seas has purchased an aggregate of $7,500,000 of our Class A common
stock; or
|
●
|
The
second anniversary from the Effective Date.
|
|
●
|
Within
30 days of the date of this agreement, a warrant for six hundred
thousand shares of the Company’s common stock to be
exercisable on the 14 month anniversary of this agreement for a
period of 12 months with a cashless exercise
provision.
|
|
●
|
Within
30 days of the date of this agreement, a warrant for one million
shares of the Company’s common stock to be exercisable on the
20 month anniversary of this agreement for a period of 12 months
with a cashless exercise provision.
|
|
●
|
Within
30 days of the date of this agreement, a warrant for two million
shares of the Company’s common stock to be exercisable on the
32 month anniversary of this agreement for a period of 12 months
with a cashless exercise provision.
|
|
●
|
Based
on the consultants reaching two sets of benchmarks, two separate
warrants for one million five hundred thousand shares of the
Company’s common stock to be exercisable on the 28 month
anniversary of this agreement for a period of 12 months with a
cashless exercise provision.
|
|
●
|
On the
three year anniversary, assuming the consultant acted in good faith
and the Company’s board of directors approval, a warrant for
one million five hundred thousand shares of the Company’s
common stock to be exercisable on the 28 month anniversary of this
agreement for a period of 12 months with a cashless exercise
provision.
|
–
|
Lack of internal audit function
. During 2017, the
Company, upon review of the independent auditors, made some
adjustments to its financial statements, including, adjusting
salary amounts and the related tax accruals, correcting warrant
expense for a warrant issued to a related party, and adding the
liability due to our attorney that should have been
recorded. Management believes that the foregoing is due
to the fact that the Company lacks qualified resources to perform
the internal audit functions properly and that the scope and
effectiveness of the internal audit function are yet to be
developed. Specifically, the reporting mechanism between the
accounting department and the Board of Directors and the CEO was
not effective, therefore resulting in the delay of recording and
reporting.
|
|
|
–
|
No Segregation of Duties Ineffective controls over financial
reporting
: As of December 31, 2017, we had no full-time
employees with the requisite expertise in the key functional areas
of finance and accounting. As a result, there is a lack of proper
segregation of duties necessary to insure that all transactions are
accounted for accurately and in a timely manner.
|
|
|
–
|
Lack of a functioning audit committee
: Due to a lack of a
majority of independent members and a lack of a majority of outside
directors on our board of directors, and no audit committee has
been elected, the oversight in the establishment and monitoring of
required internal controls and procedures is
inadequate.
|
|
|
–
|
Written Policies & Procedures
: Due to lack of written
policies and procedures for accounting and financial reporting, the
Company did not establish a formal process to close our books
monthly and account for all transactions.
|
|
|
–
|
Lack of controls
over related party transactions:
As of
December 31, 2017, the Company did not establish a formal written
policy for the approval, identification and authorization of
related party transactions.
|
1.
|
We will
continue to educate our management personnel to increase its
ability to comply with the disclosure requirements and financial
reporting controls; and
|
2.
|
We will
increase management oversight of accounting and reporting functions
in the future; and
|
3.
|
As soon
as we can raise sufficient capital or our operations generate
sufficient cash flow, we will hire personnel to handle our
accounting and reporting functions.
|
NAME
|
AGE
|
POSITION
|
DATE
APPOINTED
|
|
|
|
|
Kim
Thompson
|
56
|
President, Chief
Executive Officer, Chief Financial Officer and
Director
|
April 25,
2006
|
Jonathan R.
Rice
|
38
|
Chief Operating
Officer
|
January 20,
2015
|
1)
|
In
2017, Kim Thompson received $31,997 in medical insurance and
medical reimbursement pursuant to an employment agreement entered
into with us. In 2017, Kim Thompson received $15,143 in
reimbursement for office and travel related expenses.
|
2)
|
In
2016, Kim Thompson received $29,613 in medical insurance and
medical reimbursement pursuant to an employment agreement entered
into with us. In 2016, Kim Thompson received $14,996 in
reimbursement for office and travel related expenses.
|
3)
|
In
2017, Jonathan Rice received $15,930 in medical insurance and
medical reimbursement, $1,040 in phone service expenses, pursuant
to an employment agreement entered into with us.
|
4)
|
In
2016, Jonathan Rice received $10,925 in medical insurance and
medical reimbursement, $1,040 in phone service expenses, and $
5,250 in tuition reimbursements pursuant to an employment agreement
entered into with us.
|
|
|
Title
of Class
|
Name
and Address of Beneficial Owner
|
Amount and Nature of
Beneficial
|
|
Percent
of Class (1)
|
|
|
|
|
|
Class A Common
Stock
|
Kim
Thompson
|
230,266,109
|
(2
)
|
28.18
%
|
|
2723 South State St
Suite 150
|
|
|
|
|
Ann Arbor, MI
48104
|
|
|
|
|
|
|
|
|
Class A Common
Stock
|
Jonathan R.
Rice
|
11,000,000
|
(3
)
|
1.34
%
|
|
2723 South State St
Suite 150
|
|
|
|
|
Ann Arbor, MI
48104
|
|
|
|
|
|
|
|
|
Class A Common
Stock
|
All executive
officers and directors as a group (2 Person)
|
241,266,109
|
|
29.52
%
|
|
|
|
|
|
Series A Preferred
Stock
|
Kim
Thompson
|
2
|
|
100
%
|
|
2723 South State St
Suite 150
|
|
|
|
|
Ann Arbor, MI
48104
|
|
|
|
|
|
|
|
|
Series A Preferred
Stock
|
All executive
officers and directors as a group (1 Person)
|
2
|
|
100
%
|
|
2017
|
2016
|
Audit
Fees
|
$
17,900
|
$
18,800
|
Audit-Related
Fees
|
-
|
-
|
Tax
Fees
|
$
27,352
|
-
|
All Other
Fees
|
-
|
-
|
Total
|
$
45,252
|
$
18,800
|
●
|
approved
by our audit committee; or
|
●
|
entered
into pursuant to pre-approval policies and procedures established
by the audit committee, provided the policies and procedures are
detailed as to the particular service, the audit committee is
informed of each service, and such policies and procedures do not
include delegation of the audit committee's responsibilities to
management.
|
1.
|
The
financial statements listed in the “Index to Financial
Statements” at page F-1 are filed as part of this report. The
financial statements listed in the “Index to Financial
Statements” at page F-1 are filed as part of this
report.
|
2.
|
Financial statement schedules are omitted because they are not
applicable or the required information is shown in the financial
statements or notes thereto.
|
3.
|
Exhibits included or incorporated herein: see index to
Exhibits.
|
(b)
Exhibits
|
|
|
EXHIBIT NUMBER
|
|
DESCRIPTION
|
|
|
|
3.1
|
|
Articles
of Incorporation (1)
|
|
|
|
3.2
|
|
Articles
of Amendment (3)
|
|
|
|
3.3
|
|
Articles
of Amendment, filed with the Wyoming Secretary of State on November
15, 2013 (6)
|
|
|
|
3.4
|
|
Articles
of Amendment, filed with the Wyoming Secretary of State on December
17, 2013 (7)
|
|
|
|
3.5
|
|
By-Laws (1)
|
|
|
|
4.1
|
|
Form of
Warrant issued Mr. Jonathan R. Rice
|
|
|
|
10.1
|
|
Employment
Agreement, dated November 10, 2010, by and between Kraig Biocraft
Laboratories, Inc. and Kim Thompson (8)
|
|
|
|
10.2
|
|
Securities
Purchase Agreement between Kraig Biocraft Laboratories and Worth
Equity Fund, L.P. and Mutual Release (1)
|
10.3
|
|
Securities
Purchase Agreement between Kraig Biocraft Laboratories and Lion
Equity (1)
|
|
|
|
10.4
|
|
Amended
Letter Agreement, dated September 14, 2009, by and between Kraig
Biocraft Laboratories and Calm Seas Capital,
LLC (3)
|
|
|
|
10.5
|
|
Exclusive
License Agreement, effective as of May 8, 2006, by and between The
University of Wyoming and Kraig Biocraft Laboratories,
Inc. (2)
|
|
|
|
10.6
|
|
Addendum
to the Founder’s Stock Purchase and Intellectual Property
Transfer Agreement, dated December 26, 2006, and the
Founder’s Stock Purchase and Intellectual Property Transfer
Agreement dated April 26, 2006 (3)
|
|
|
|
10.7
|
|
Intellectual
Property/Collaborative Research Agreement, dated March 20, 2010, by
and between Kraig Biocraft Laboratories and The University of Notre
Dame du Lac. (2)
|
|
|
|
10.8
|
|
Letter
Agreement, dated June 28, 2011, by and between Kraig Biocraft
Laboratories and Calm Seas Capital, LLC (4)
|
|
|
|
10.9
|
|
Letter
Agreement, dated April 30, 2013, by and between Kraig Biocraft
Laboratories and Calm Seas Capital, LLC (5)
|
|
|
|
10.1
|
|
Letter
Agreement, dated October 2, 2014, by and between Kraig Biocraft
Laboratories and Calm Seas Capital, LLC (10)
|
|
|
|
10.11
|
|
License
Agreement, dated October 28, 2011, between the Company and
University of Notre Dame du Lac. (12)
|
|
|
|
10.12
|
|
Intellectual
Property / Collaborative Research Agreement, dated June 6, 2012,
between the Company and University of Notre Dame du
Lac. (12)
|
|
|
|
10.13
|
|
Collaborative
Yarn and Textile Development Agreement, dated September 30, 2013,
between the Company and Warwick Mills, Inc. (12)
|
|
|
|
10.14
|
|
Employment
Agreement, dated January 19, 2015, between the Company and Mr.
Jonathan R. Rice (11)
|
|
|
|
10.15
|
|
Intellectual
Property / Collaborative Research Agreement, dated March 4, 2015,
between the Company and University of Notre Dame du
Lac.
|
|
|
|
14.1
|
|
Code of
Business Conduct and Ethics (13)
|
|
|
|
31.1
|
|
Certification
of Chief Executive Officer/Chief Financial Officer pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002 *
|
|
|
|
31.2
|
|
Certification
of Chief Executive Officer/Chief Financial Officer pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002 *
|
|
|
|
101
|
|
Interactive
data files #
|
|
Kraig Biocraft Laboratories, Inc.
|
|
|
|
|
|
|
Dated: March 23, 2018
|
By:
|
/s/ Kim
Thompson
|
|
|
|
Kim
Thompson
|
|
|
|
President,
Chief Executive Officer and Chief Financial Officer
|
|
|
|
(Principal
Executive Officer and Principal Financial and Accounting
Officer)
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/
Kim Thompson
|
|
President,
Chief Executive Officer, Chief Financial Officer and Sole
Director
|
|
March 23, 2018
|
Kim
Thompson
|
|
|
|
|
1 Year Kraig Biocraft Laborator... (QB) Chart |
1 Month Kraig Biocraft Laborator... (QB) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions